

BIOCRYST PHARMACEUTICALS INC

Form 8-K

March 09, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: March 7, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**

(Address of Principal Executive Office)

**(205) 444-4600**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
-

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On March 7, 2005, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the Company) adopted an amendment to Section 2.2 of the Company's by-laws to delete the mandatory retirement age for directors of the Company. Previously, no person was eligible for election or reelection as a director of the Company after such person had reached his or her 70<sup>th</sup> birthday.

A complete copy of the Company's By-laws, as amended, is attached as Exhibit 3.1 to this Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits:**

**Exhibit No.**

**Description**

---

3.1	By-laws of the Company as amended March 7, 2005.
-----	--

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 9, 2005

BIOCRYST PHARMACEUTICALS, INC.

By: \_\_\_\_\_ /s/ MICHAEL A. DARWIN

**Michael A. Darwin**  
Chief Financial Officer and Chief  
Accounting Officer

**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
3.1	By-laws of the Company as amended March 7, 2005.

4